Mucopolysaccharidosis IV - 18 Studies Found
| Completed |
: A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) : MPS IV A : 2011-01-10 :
|
| Approved for marketing |
: BMN 110 US Expanded Access Program :
: 2013-05-15 : Drug: BMN 110 |
| Terminated |
: A Study to Evaluate the Long-Term Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) :
: 2010-10-28 : Drug: BMN 110 Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of |
| Completed |
: A Study to Evaluate the Safety, Tolerability and Efficacy of BMN 110 in Subjects With Mucopolysaccharidosis IVA : MPS IV A : 2009-04-10 : Drug: BMN 110 Subjects will receive a weekly 4- to 5-hour |
| Enrolling by invitation |
: BMN 110 Phase 3B in Australian Patients : Mucopolysaccharidosis IVA (Morquio A Syndrome) : 2013-09-10 : Drug: BMN 110 All pateints receive treatment with BMN 110 |
| Terminated |
: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation :
: 2012-09-17 : Drug: BMN 110 Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2. |
| Terminated |
: Safety and Exercise Study of Two Doses of BMN 110 for Morquio A Syndrome :
: 2012-05-24 : |
| Completed |
: Study of BMN 110 in Pediatric Patients < 5 Years of Age With Mucopolysaccharidosis IVA (Morquio A Syndrome) :
: 2011-12-22 : Drug: BMN 110 Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk o |